Type 1 diabetes is an autoimmune disease that destroys insulin production by pancreatic islet cells, leading to a chronic and challenging-to-manage disease. With 40,000 new cases annually, type 1 diabetes affects more than 1.25 million Americans, with peak diagnosis in children between the ages of 2 and 17. Up to 40 percent of new cases are diagnosed with potentially life-threatening conditions such as diabetic ketoacidosis. Autoantibody markers appear well in advance of symptoms, and pilot studies have shown that screening for these markers can reduce the rates of often-deadly diabetic ketoacidosis at diagnosis, reduce medical complications and potentially improve patients’ quality of life.
Screening using ultrasensitive and low-cost assays reduces incidence rates of DKA and can contribute to finding a cure.
Enable Biosciences’s ADAP assay for T1D was among the top performing assays in the world as presented at the Immunology of Diabetes Society (IDS) Congress in 2018.
Enable Biosciences has partnered with Hamilton Robotics to bring the improved assay to the Enable ADAP STAR platform, allowing for high-throughput population screening.
This product is available for Research and Clinical Diagnostics. We offer Clinical and Research Testing Services and Automated Workstations. Contact us at firstname.lastname@example.org
Type 1 diabetes is an autoimmune disease that affects 1-2 million Americans, mostly young children.
40% of new cases are diagnosed with diabetic ketoacidosis, a potentially life-threatening condition.
Autoantibody biomarkers appear years in advance of symptoms.
Testing for autoantibodies can reduce rates of medical complications and potentially improve quality of life.
Current tests are expensive, slow, or may miss critical diagnoses.
CDC National Diabetes Statistics Report, 2014.
Diabetes Care 2017 Sep; 40(9): 1249-1255.
Diabetes Care 2015 Jun; 38(6): 989-996.
Diabetes Care 2003 Jan; 26(suppl 1): s33-s50.